Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversibly binding P2Y12 platelet inhibitor.
## Primary Indications
* Reduction of thrombotic cardiovascular events in patients with Acute Coronary Syndrome (ACS) or a history of Myocardial Infarction (MI).
* Prevention of stent thrombosis in patients treated with drug-eluting stents.
## Adult Dosing
* **ACS:**
* Loading dose: 180 mg orally once.
* Maintenance dose: 90 mg orally twice daily.
* **Post-MI (beyond 1 year after ACS or stent placement):**
* For patients with a history of MI at least 1 year ago and at high risk for occlusive thrombotic events, who are also treated with aspirin: 60 mg orally twice daily.
## Pediatric Dosing
No established pediatric dosing. Ticagrelor is not recommended for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is recommended in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is needed for mild, moderate, or severe renal impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
* History of intracranial hemorrhage.
## Adverse Effects
* **Major Bleeding:** The most significant risk. Can occur anywhere and may be life-threatening.
* **Dyspnea:** Common, usually mild and transient.
* **Bradycardia:** Can occur due to adenosine release.
* **Ventricular pauses.**
* **Hyperuricemia and gout.**
* **Increased serum creatinine.**
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) may increase ticagrelor exposure.
* **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure.
* **Statins:** Ticagrelor can increase the exposure of simvastatin and atorvastatin. Consider dose reduction or alternatives if clinically indicated.
* **Aspirin:** Concurrent use is generally recommended for ACS, but increases bleeding risk. Long-term use beyond 1 year in post-MI patients may also increase bleeding risk.
* **Other Antiplatelets/Anticoagulants:** Concomitant use increases the risk of bleeding.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding.
* **Renal function and uric acid levels:** Periodically monitor, especially in patients with pre-existing renal impairment or hyperuricemia.
* **Heart rate:** Monitor for bradycardia, especially in patients with pre-existing conditions predisposing to bradycardia.
## Clinical Pearls
* Ticagrelor is a potent P2Y12 inhibitor with a rapid onset and offset of action.
* The 90 mg twice-daily dose is generally preferred in ACS for its balance of efficacy and safety compared to the 60 mg dose.
* The 60 mg twice-daily dose is approved for long-term maintenance in select post-MI patients.
* Patients should be advised to report any signs of bleeding immediately.
* Discontinuation of ticagrelor should be avoided if possible, as it increases the risk of thrombotic events. If discontinuation is necessary, consider the risks and benefits.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for the most current and complete drug information.*
